BUZZ-Genscript hits 4-week high on associate's promising blood cancer cell therapy

Legend Biotech

Legend Biotech

LEGN

0.00

** Shares of Genscript Biotech Corp 1548.HK jump 28.5% to HK$15.6, their highest level since May 8, and on course to snap a four-session slide

** Stock last up 17.8%, on track for biggest one-day pct rise since July 2024

** Co says associate Legend Biotech Corp LEGN.O will announce promising preliminary clinical data of its blood cancer therapy at European Hematology Association 2026 Congress in Sweden in mid-June

** Legend Biotech's experimental cell therapy shows early signs that its approach of generating disease-fighting cells within patients may work for a type of blood cancer

** U.S.-listed stock of Legend Biotech soared 42.2% on Tuesday

** YTD, Genscript stock up 16.2%, Legend Biotech up 66.9%, while Hang Seng Biotech Index .HSBIO down 10.3%


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.